Welireg, Padcev, and a surprise fillip for Flare.
ApexOnco Front Page
Recent articles
Two new pivotal Chinese first-line trials have started in lung cancer.
AZD0120’s first pivotal trial will test settings as early as the second line.
The company will start a phase 2/3 trial of PF-08634404 in March.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
